Skip to Content
Menu

Mesothelioma clinical trials only accept a certain number of patients. Once that number is reached, the study halts enrollment. Doctors continue treating and monitoring enrolled patients until the study ends. Ongoing clinical trials provide important information about new mesothelioma treatments.


01. Ongoing Clinical Trials

Ongoing Mesothelioma Clinical Trials

Clinical trials are designed to test new treatments as efficiently as possible. Part of this design means only a certain number of patients can be accepted into each study. Once a mesothelioma study reaches this enrollment target, no additional mesothelioma patients are accepted. The study is still considered to be ongoing, as doctors continue treating and monitoring existing study patients.

Some clinical trials release preliminary study results during this time period. For instance, the CheckMate 743 clinical trial did this in 2020. CheckMate 743 investigated the use of two immunotherapy drugs compared to standard chemotherapy treatment.

Nivolumab and ipilimumab are known as the brand names Opdivo® and Yervoy®, respectively.

The immunotherapy drug combination (nivolumab and ipilimumab) performed better than standard chemotherapy. Patients treated with the immunotherapy drugs lived about four months longer than those receiving chemotherapy.

After reviewing the study results, the U.S. Food and Drug Administration (FDA) approved the immunotherapy drugs. Specifically, nivolumab and ipilimumab were approved for the treatment of inoperable pleural mesothelioma.

If you or a loved one are considering enrolling in a clinical trial, you can find open studies on our Clinical Trials – Recruiting page.

02. List of Ongoing Clinical Trials

Ongoing Mesothelioma Clinical Trials Not Recruiting Patients

Provided below is a list of mesothelioma trials that are no longer accepting new patients.

Note: The information below is provided by ClinicalTrials.gov.

A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies


Conditions:

Last Updated: January 27, 2022

Status: Active, not recruiting

Locations: Chicago, IL. Bethesda, MD. Nashville, TN. Dallas, TX.

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms

Last Updated: January 27, 2022

Status: Active, not recruiting

Locations: Phoenix, AZ. Scottsdale, AZ. Hot Springs, AR. Arroyo Grande, CA. Duarte, CA. Sacramento, CA. Colorado Springs, CO. Colorado Springs, CO. Denver, CO. Durango, CO. Durango, CO. Golden, CO. Lakewood, CO. Lakewood, CO. Littleton, CO. Longmont, CO. Longmont, CO. Parker, CO. Parker, CO. Pueblo, CO. Pueblo, CO. Thornton, CO. Jacksonville, FL. Boise, ID. Caldwell, ID. Coeur d'Alene, ID. Meridian, ID. Nampa, ID. Post Falls, ID. Sandpoint, ID. Aurora, IL. Bloomington, IL. Canton, IL. Carbondale, IL. Carterville, IL. Carthage, IL. Centralia, IL. Danville, IL. Decatur, IL. Decatur, IL. Effingham, IL. Effingham, IL. Eureka, IL. Galesburg, IL. Galesburg, IL. Kewanee, IL. Macomb, IL. Mattoon, IL. O'Fallon, IL. Ottawa, IL. Pekin, IL. Pekin, IL. Peoria, IL. Peoria, IL. Peoria, IL. Peoria, IL. Peru, IL. Peru, IL. Princeton, IL. Springfield, IL. Springfield, IL. Springfield, IL. Swansea, IL. Urbana, IL. Urbana, IL. Yorkville, IL. Ames, IA. Ames, IA. Boone, IA. Clive, IA. Clive, IA. Council Bluffs, IA. Creston, IA. Des Moines, IA. Des Moines, IA. Fort Dodge, IA. Jefferson, IA. Marshalltown, IA. West Des Moines, IA. Lawrence, KS. Wichita, KS. Wichita, KS. Wichita, KS. Bardstown, KY. Corbin, KY. Lexington, KY. Lexington, KY. London, KY. Louisville, KY. Louisville, KY. Louisville, KY. Shepherdsville, KY. New Orleans, LA. Brownstown, MI. Clinton Township, MI. Detroit, MI. Jackson, MI. Shelby, MI. West Bloomfield, MI. Rochester, MN. Bonne Terre, MO. Cape Girardeau, MO. Cape Girardeau, MO. Jefferson City, MO. Saint Louis, MO. Sainte Genevieve, MO. Sullivan, MO. Sunset Hills, MO. Anaconda, MT. Billings, MT. Bozeman, MT. Great Falls, MT. Great Falls, MT. Helena, MT. Kalispell, MT. Missoula, MT. Grand Island, NE. Kearney, NE. Kearney, NE. Lincoln, NE. Omaha, NE. Omaha, NE. Omaha, NE. Omaha, NE. Omaha, NE. Papillion, NE. Henderson, NV. Henderson, NV. Las Vegas, NV. Las Vegas, NV. Las Vegas, NV. Las Vegas, NV. Las Vegas, NV. Las Vegas, NV. Las Vegas, NV. Las Vegas, NV. Las Vegas, NV. Las Vegas, NV. Las Vegas, NV. Reno, NV. Reno, NV. Reno, NV. Cincinnati, OH. Cincinnati, OH. Cincinnati, OH. Cincinnati, OH. Lawton, OK. Oklahoma City, OK. Pittsburgh, PA. Charleston, SC. Chattanooga, TN. Hixson, TN. Ooltewah, TN. Bryan, TX. Conroe, TX. Dallas, TX. Houston, TX. Houston, TX. Houston, TX. League City, TX. Richardson, TX. Sugar Land, TX. Charlottesville, VA. Bellevue, WA. Bremerton, WA. Bremerton, WA. Burien, WA. Enumclaw, WA. Federal Way, WA. Lakewood, WA. Poulsbo, WA. Renton, WA. Seattle, WA. Seattle, WA. Seattle, WA. Tacoma, WA. Tacoma, WA. Cody, WY. Sheridan, WY.

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: January 25, 2022

Status: Active, not recruiting

Locations: Houston, TX.

Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: January 24, 2022

Status: Active, not recruiting

Locations: Phoenix, AZ. Los Angeles, CA. San Francisco, CA. Tampa, FL. Chicago, IL. Baltimore, MD. Detroit, MI. Rochester, MN. New York, NY. Houston, TX. Alessandria, Alabama. Milano, Michigan.

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms

Last Updated: January 22, 2022

Status: Active, not recruiting

Locations: Rogers, AR. Antioch, CA. Burbank, CA. Fremont, CA. Fresno, CA. Los Angeles, CA. Los Angeles, CA. Modesto, CA. Oakland, CA. Orange, CA. Redwood City, CA. Richmond, CA. Roseville, CA. Sacramento, CA. Sacramento, CA. Sacramento, CA. San Francisco, CA. San Jose, CA. San Leandro, CA. San Rafael, CA. Santa Clara, CA. Santa Rosa, CA. South San Francisco, CA. Stockton, CA. Vacaville, CA. Vallejo, CA. Walnut Creek, CA. Hartford, CT. Orlando, FL. Gainesville, GA. 'Aiea, HI. 'Aiea, HI. Honolulu, HI. Honolulu, HI. Honolulu, HI. Honolulu, HI. Honolulu, HI. Honolulu, HI. Honolulu, HI. Honolulu, HI. Honolulu, HI. Kailua, HI. Lihue, HI. Boise, ID. Coeur d'Alene, ID. Post Falls, ID. Sandpoint, ID. Bloomington, IL. Bloomington, IL. Canton, IL. Carbondale, IL. Carthage, IL. Centralia, IL. Decatur, IL. Decatur, IL. Decatur, IL. Effingham, IL. Eureka, IL. Galesburg, IL. Galesburg, IL. Kewanee, IL. Macomb, IL. O'Fallon, IL. Ottawa, IL. Ottawa, IL. Pekin, IL. Pekin, IL. Peoria, IL. Peoria, IL. Peoria, IL. Peoria, IL. Peru, IL. Peru, IL. Princeton, IL. Springfield, IL. Springfield, IL. Springfield, IL. Springfield, IL. Beech Grove, IN. Indianapolis, IN. Richmond, IN. Topeka, KS. Crestview Hills, KY. Lexington, KY. Ann Arbor, MI. Ann Arbor, MI. Ann Arbor, MI. Dearborn, MI. Detroit, MI. Detroit, MI. Detroit, MI. Farmington Hills, MI. Flint, MI. Flint, MI. Flint, MI. Jackson, MI. Lansing, MI. Livonia, MI. Pontiac, MI. Port Huron, MI. Saginaw, MI. Warren, MI. Pascagoula, MS. Bonne Terre, MO. Cape Girardeau, MO. Cape Girardeau, MO. Jefferson City, MO. Saint Louis, MO. Sainte Genevieve, MO. Sullivan, MO. Sunset Hills, MO. Anaconda, MT. Billings, MT. Billings, MT. Billings, MT. Billings, MT. Bozeman, MT. Butte, MT. Great Falls, MT. Great Falls, MT. Helena, MT. Kalispell, MT. Kalispell, MT. Missoula, MT. Missoula, MT. Missoula, MT. Charlotte, NC. Charlotte, NC. Charlotte, NC. Charlotte, NC. Hendersonville, NC. Hendersonville, NC. Huntersville, NC. Huntersville, NC. Matthews, NC. Matthews, NC. Mooresville, NC. Statesville, NC. Winston-Salem, NC. Belpre, OH. Chillicothe, OH. Cincinnati, OH. Cincinnati, OH. Cincinnati, OH. Cincinnati, OH. Cincinnati, OH. Columbus, OH. Columbus, OH. Columbus, OH. Columbus, OH. Columbus, OH. Columbus, OH. Columbus, OH. Columbus, OH. Dayton, OH. Dayton, OH. Dayton, OH. Dayton, OH. Dayton, OH. Delaware, OH. Delaware, OH. Delaware, OH. Fairfield, OH. Findlay, OH. Franklin, OH. Greenville, OH. Kettering, OH. Lancaster, OH. Mansfield, OH. Marietta, OH. Marion, OH. Mount Vernon, OH. Newark, OH. Newark, OH. Portsmouth, OH. Springfield, OH. Troy, OH. Westerville, OH. Xenia, OH. Zanesville, OH. Clackamas, OR. Milwaukie, OR. Newberg, OR. Oregon City, OR. Portland, OR. Portland, OR. Boiling Springs, SC. Easley, SC. Greenville, SC. Greenville, SC. Greenville, SC. Greenville, SC. Greenville, SC. Greer, SC. Seneca, SC. Bristol, TN. Bristol, TN. Johnson City, TN. Kingsport, TN. Kingsport, TN. Houston, TX. Danville, VA. Norton, VA. Anacortes, WA. Bellingham, WA. Bremerton, WA. Burien, WA. Edmonds, WA. Issaquah, WA. Kennewick, WA. Kirkland, WA. Longview, WA. Mount Vernon, WA. Poulsbo, WA. Seattle, WA. Seattle, WA. Seattle, WA. Seattle, WA. Seattle, WA. Seattle, WA. Seattle, WA. Sedro-Woolley, WA. Spokane, WA. Spokane, WA. Spokane, WA. Vancouver, WA. Vancouver, WA. Wenatchee, WA. Casper, WY. Cody, WY. Cody, WY. Sheridan, WY.

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors


Conditions: Neoplasms, Mesothelioma, Breast Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Liver Neoplasms, Carcinoma, Renal Cell, Prostatic Neoplasms, Neoplasms, Squamous Cell

Last Updated: January 21, 2022

Status: Active, not recruiting

Locations: Scottsdale, AZ. Santa Monica, CA. Norwich, CT. Boston, MA. Boston, MA. Boston, MA. Danvers, MA. Newton, MA. Las Vegas, NV. Oklahoma City, OK. Oklahoma City, OK. Nashville, TN. Nashville, TN. Houston, TX. San Antonio, TX.

Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma


Conditions: Vaccinia, Mesothelioma, Pleural Effusion, Malignant, Pleural Effusion

Last Updated: January 19, 2022

Status: Active, not recruiting

Locations: New York, NY.

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors


Conditions: Carcinoma, Merkel Cell, Carcinoma, Carcinoma, Squamous Cell, Mesothelioma, Mesothelioma, Malignant, Neuroendocrine Tumors, Nasopharyngeal Carcinoma, Lung Neoplasms, Carcinoma, Neuroendocrine

Last Updated: January 18, 2022

Status: Active, not recruiting

Locations: Houston, TX.

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin


Conditions: Neoplasms, Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms

Last Updated: January 15, 2022

Status: Active, not recruiting

Locations: Duarte, CA. Los Angeles, CA. Los Angeles, CA. Pasadena, CA. Sacramento, CA. Aurora, CO. Baltimore, MD. Ann Arbor, MI. Rochester, MN. Columbus, OH. Pittsburgh, PA. Nashville, TN. Nashville, TN. Madison, WI.

First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: January 11, 2022

Status: Active, not recruiting

Locations: Bethesda, MD. Houston, TX.

The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance


Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Mesothelioma, Mesothelioma, Malignant

Last Updated: January 11, 2022

Status: Active, not recruiting

Locations: Boston, MA.

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: January 6, 2022

Status: Active, not recruiting

Locations: Alessandria, Alabama. Catania, Connecticut.

A Study of LY3023414 in Participants With Advanced Cancer


Conditions: Neoplasms, Mesothelioma, Mesothelioma, Malignant

Last Updated: January 5, 2022

Status: Active, not recruiting

Locations: Los Angeles, CA. New York, NY. Oklahoma City, OK. Philadelphia, PA. Nashville, TN. Nashville, TN.

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)


Conditions: Neoplasms, Melanoma, Carcinoma, Renal Cell, Mesothelioma, Mesothelioma, Malignant, Cholangiocarcinoma

Last Updated: December 23, 2021

Status: Active, not recruiting

Locations: Gainesville, FL. Miami, FL. Orlando, FL.

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors


Conditions: Carcinoma, Renal Cell, Mesothelioma

Last Updated: December 22, 2021

Status: Active, not recruiting

Locations: Mobile, AL. Scottsdale, AZ. Tucson, AZ. Baltimore, MD. Boston, MA. Boston, MA. Detroit, MI. Nashville, TN. Nashville, TN. Houston, TX. Houston, TX. San Antonio, TX.

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies


Conditions: Neoplasms

Last Updated: December 21, 2021

Status: Active, not recruiting

Locations: Los Angeles, CA. Gainesville, FL. Detroit, MI. Saint Louis, MO. Hackensack, NJ. New York, NY. Chapel Hill, NC. Oklahoma City, OK. Portland, OR. Philadelphia, PA. Pittsburgh, PA. Nashville, TN. Dallas, TX. Houston, TX. Seattle, WA.

Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study


Conditions: Lymphoma, Sarcoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Mesothelioma, Sarcoma, Synovial, Carcinoma, Medullary

Last Updated: December 8, 2021

Status: Active, not recruiting

Locations: Tucson, AZ. Tampa, FL. Ann Arbor, MI. New York, NY. New York, NY.

Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: November 30, 2021

Status: Active, not recruiting

Locations: Tampa, FL.

Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: November 10, 2021

Status: Active, not recruiting

Locations: La Jolla, CA. Los Angeles, CA. Stanford, CA. Aurora, CO. Miami, FL. Atlanta, GA. Chicago, IL. Evanston, IL. Baltimore, MD. Ann Arbor, MI. Saint Louis Park, MN. Saint Louis, MO. New Brunswick, NJ. New York, NY. Philadelphia, PA. Pittsburgh, PA. Dallas, TX. Fairfax, VA. Seattle, WA. Wauwatosa, WI.

CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: November 6, 2021

Status: Active, not recruiting

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin


Conditions: Mesothelioma, Pleural Diseases

Last Updated: October 29, 2021

Status: Active, not recruiting

Locations: Basking Ridge, NJ. Middletown, NJ. Montvale, NJ. Commack, NY. Harrison, NY. New York, NY.

Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: October 25, 2021

Status: Active, not recruiting

Locations: Los Angeles, CA. San Francisco, CA. Tampa, FL. Kansas City, KS. Baltimore, MD. Baltimore, MD. Minneapolis, MN. Rochester, MN. New York, NY. Philadelphia, PA. Dallas, TX.

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms

Last Updated: October 20, 2021

Status: Active, not recruiting

Locations: Scottsdale, AZ. La Jolla, CA. Los Angeles, CA. San Francisco, CA. Santa Monica, CA. New Haven, CT. Newark, DE. Tampa, FL. Augusta, GA. Chicago, IL. Peoria, IL. Baltimore, MD. Baltimore, MD. Minneapolis, MN. New York, NY. Rochester, NY. Durham, NC. Canton, OH. Philadelphia, PA. Dallas, TX. Houston, TX.

Phase I Trial HIPEC With Nal-irinotecan


Conditions: Mesothelioma, Adenocarcinoma, Mucinous, Cystadenocarcinoma, Pseudomyxoma Peritonei

Last Updated: October 19, 2021

Status: Active, not recruiting

Locations: Lexington, KY. Stony Brook, NY.

Pembrolizumab in Treating Patients With Malignant Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms

Last Updated: October 8, 2021

Status: Active, not recruiting

Locations: Chicago, IL.

A Comparative Study Between Regional Anesthesia in Thoracoscopes and the Conventional General Anesthesia


Conditions: Empyema, Empyema, Pleural, Mesothelioma, Pleural Effusion, Malignant, Pleural Neoplasms, Pleural Effusion, Pulmonary Atelectasis, Pneumothorax, Pleural Diseases, Hemothorax, Pericardial Effusion, Lymphadenopathy

Last Updated: September 30, 2021

Status: Active, not recruiting

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors


Conditions: Adenocarcinoma, Mesothelioma, Cholangiocarcinoma

Last Updated: September 29, 2021

Status: Active, not recruiting

Locations: Bethesda, MD.

Intrapleural Cryotherapy for Malignant Pleural Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: September 14, 2021

Status: Active, not recruiting

Locations: Rochester, MN.

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549


Conditions: Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms, Mesothelioma, Mesothelioma, Malignant, Neoplasms, Squamous Cell, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Adrenocortical Carcinoma

Last Updated: September 13, 2021

Status: Active, not recruiting

Locations: San Diego, CA. Santa Monica, CA. Port Saint Lucie, FL. Atlanta, GA. Boston, MA. Boston, MA. Boston, MA. Hackensack, NJ. New York, NY. Houston, TX. San Antonio, TX.

Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: September 10, 2021

Status: Active, not recruiting

Locations: Basking Ridge, NJ. Middletown, NJ. Montvale, NJ. Commack, NY. Harrison, NY. New York, NY. Rockville Centre, NY. Uniondale, NY.

A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: September 8, 2021

Status: Active, not recruiting

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors


Conditions: Neoplasms

Last Updated: August 10, 2021

Status: Active, not recruiting

Locations: San Francisco, CA. Santa Monica, CA. Chicago, IL. Kansas City, KS. Charlotte, NC. Columbus, OH. Nashville, TN. Houston, TX. San Antonio, TX.

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors


Conditions: Neoplasms

Last Updated: July 29, 2021

Status: Active, not recruiting

Locations: La Jolla, CA. Sacramento, CA. Stanford, CA. New Haven, CT. Huntersville, NC. Greenville, SC. Dallas, TX. San Antonio, TX. Charlottesville, VA. Fairfax, VA.

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: June 15, 2021

Status: Active, not recruiting

Locations: Houston, TX.

Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms

Last Updated: June 11, 2021

Status: Active, not recruiting

Locations: Basking Ridge, NJ. Middletown, NJ. Commack, NY. Harrison, NY. New York, NY. Rockville Centre, NY. Uniondale, NY.

Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: May 10, 2021

Status: Active, not recruiting

Locations: New York, NY.

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors


Conditions: Neoplasms

Last Updated: May 3, 2021

Status: Active, not recruiting

Locations: La Jolla, CA. Chicago, IL. Huntersville, NC. San Antonio, TX. Fairfax, VA.

TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: April 11, 2021

Status: Active, not recruiting

Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: March 24, 2021

Status: Active, not recruiting

Locations: San Francisco, CA. New Haven, CT. Tampa, FL. Chicago, IL. Baltimore, MD. Detroit, MI. Grand Rapids, MI. Rochester, MN. New York, NY. Cleveland, OH. Jefferson Hills, PA. Philadelphia, PA. Houston, TX. Morgantown, WV.

Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma


Conditions: Lung Neoplasms, Mesothelioma, Mesothelioma, Malignant

Last Updated: March 4, 2021

Status: Active, not recruiting

PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: February 8, 2021

Status: Active, not recruiting

A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: July 29, 2020

Status: Active, not recruiting

Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134


Conditions: Mesothelioma

Last Updated: May 9, 2019

Status: Active, not recruiting

Locations: New York, NY. Houston, TX.